A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):36-40.

View in: PubMed

subject areas

Administration, Intravenous
Aged
Antineoplastic Combined Chemotherapy Protocols
Cisplatin
Dose-Response Relationship, Drug
Doxorubicin
Endometrial Neoplasms
Female
Humans
Infusions, Parenteral
Middle Aged
Neoplasm Staging
Paclitaxel

authors with profiles

Joan L Walker